Drug intelligence / Profile preview

gemcitabine + 5-fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

A chemotherapy combination regimen consisting of gemcitabine, 5-fluorouracil (5-FU), and leucovorin. This protocol is primarily used for treating pancreatic cancer and biliary tract carcinomas. The standard dosing regimen includes gemcitabine 1250 mg/m² on day 1, 5-FU 450 mg/m² and leucovorin 100 mg/m² on days 1-3, repeated every 2 weeks. Clinical trials have shown moderate efficacy with manageable toxicity profiles.

Brand names: Gemzar (for gemcitabine)Adrucil (for 5-fluorouracil)Wellcovorin (for folinic acid)
Other names: leucovorin (alternative name for folinic acid)5-FU (common abbreviation for 5-fluorouracil)

Targets

TS (Thymidylate synthase)DNA polymerase familyRNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + 5-fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + 5-fluorouracil + leucovorin.

Explore the full profile